Lenvatinib Mesylate Intermediate CAS 15568-85-1 Mama>97.0% (HPLC) Falegaosimea

5-(Methoxymethylene) -2,2-Dimethyl-1,3-Dioxane-4,6-Dione (CAS: 15568-85-1) o se vaeluaga ole Lenvatinib Mesylate (CAS: 857890-39-2).Lenvatinib o se vailaʻau o le kanesa o le thyroid na atiaʻe e le Eisai Corporation o Iapani (Code: E7080), o loʻo iai i le inhibitor of oral multi-receptor tyrosine kinase (RTK) ma e mafai ona faʻalavelaveina le gaioiga kinase o le vascular endothelial growth factor (VEGF) Receptors VEGFR1 ( FLT1), VEGFR2 (KDR), ma VEGFR3 (FLT4).Lenvatinib e mafai foi ona taofia le aʻafia o isi RTK i pathological angiogenesis, tuputupu aʻe o le tuma, ma le alualu i luma o le kanesa sei vagana ai a latou galuega masani feaveaʻi e aofia ai le fibroblast growth factor (FGF) receptors FGFR1, 2, 3, ma le 4;e maua mai le platelets growth factor receptor (PDGFR [alpha]), KIT, ma le RET.[Fa'ailoga]: Lenvatinib e talafeagai mo togafitiga o gasegase o thyroid kanesa o le toe fa'afo'i mai i le lotoifale po'o le metastasis ituaiga, tulaga alualu i luma ma le radioactive iodine-refractory differentiated type.I le aso 13 o Fepuari, 2015, na faʻamaonia ai e le US FDA le vailaʻau faʻamaʻi faʻamaʻi Lenvatinib mo togafitiga o le kanesa thyroid.Lenvatinib o se fa'atosina enzyme e tele-target, e mafai ona fa'alavelaveina le VEGFR2 ma le VEGFR3 (vascular endothelial growth factor receptor).Ole igoa tau fefa'ataua'iga ole Lenvatinib ole Lenvima.I le aso 20 o Me, 2015, na faʻamaonia ai e le European Medicines Agency (EMA) le Lenvatinib mo le togafitia o faʻamaʻi pipisi, faʻa-lotoifale poʻo metastatic differentiated (papillary, follicular, Hurthle type) thyroid cancer (DTC).I le faamasinoga, o le umi o le ola mo tagata mamaʻi o le radioactive iodine-refractory DTC na togafitia ma Lenvatinib e 18 masina ae o le tau mo tagata mamaʻi e ave placebo e naʻo le 3 masina.